Results 51 to 60 of about 1,249 (168)
Controversies in NEN: An ENETS position statement on nutritional support in neuroendocrine neoplasms
Journal of Neuroendocrinology, Volume 37, Issue 12, December 2025.Abstract Neuroendocrine neoplasms (NEN) themselves and also their treatment may cause malnutrition, inducing changes in physiological behaviour and eventually leading to increased rates of morbidity and mortality. Malnutrition is a common, under‐recognised and under‐treated condition in patients with NEN, and there are limited data available on the ...
Simona Grozinsky‐Glasberg +53 more
wiley +1 more source
Reviews in Medical Virology, Volume 35, Issue 6, November 2025.ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency, characterised by impaired antibody production, immune dysregulation, and a broad spectrum of clinical manifestations. Gastrointestinal involvement is frequent, affecting up to 20% of patients and significantly contributing to morbidity and ...
Györgyi Műzes, Ferenc Sipos
wiley +1 more source
Cancer, Volume 131, Issue 17, 1 September 2025.Abstract Background Gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) account for more than 50% of all NENs. The survival of patients with GEP‐NENs has improved based on early diagnosis and improved treatment strategies. The real‐world data of GEP‐NENs in Taiwan are limited.
Hui‐Jen Tsai +19 more
wiley +1 more source
Journal of Neuroendocrinology, Volume 37, Issue 8, August 2025.Abstract Pancreatic neuroendocrine tumors (panNETs) are rare pediatric malignancies with age‐specific clinical and biological features. Data on their presentation, management, and outcomes remain limited. This retrospective study analyzed 28 pediatric panNET cases from the German Malignant Endocrine Tumor (MET) Registry enrolled between 1997 and 2024 ...
Katharina Karges +12 more
wiley +1 more source
Journal of Surgical Oncology, Volume 131, Issue 3, Page 465-472, March 2025.ABSTRACT Background Despite the well‐known prognostic role of lymph node metastasis (LNM) in pNETs, less is known about the importance of lymphovascular invasion (LVI) among patients with these tumors. Methods Patients undergoing pancreatectomy for pNET between 2002 and 2020 were identified in the US Neuroendocrine Tumor Study Group database.
Kota Sahara +12 more
wiley +1 more source
Journal of Neuroendocrinology, Volume 37, Issue 3, March 2025.Abstract Peptide receptor radionuclide therapy (PRRT) is an effective treatment for both oncological and hormone control and is a widely accepted standard of care treatment for patients with neuroendocrine neoplasms (NEN). Its use is anticipated to increase significantly, and this demands accurate tools and paradigms to assess treatment response post ...
Grace Kong +5 more
wiley +1 more source
Journal of Neuroendocrinology, Volume 37, Issue 3, March 2025.Abstract Peptide receptor radionuclide therapy (PRRT) using [177Lu‐DOTA0,Tyr3]octreotate (177Lu‐DOTATATE) represents an established treatment modality for somatostatin receptor‐positive, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours (GEP NET) of grade 1 or 2.
Jelka Kuiper +4 more
wiley +1 more source
Pancreatic VIPoma. Report of one case VIPoma pancreático. Caso clínico [PDF]
, 2010 Neuroendocrine tumors are uncommon, including VIPoma that produces vasoactive intestinal polypeptide. We report a 45-year-old female presenting with a history of diarrhea lasting three months. An abdominal CAT scan showed a solid tumor in the body of the
Urdangarín, Angélica +7 more
core
VIPoma: una causa poco frecuente de diarrea. Case repor
, 2021 Introduction: Vasoactive intestinal peptide-secreting tumor (VIPoma) is a rare functional pancreatic neuroendocrine tumor (F-PNET) characterized by secretory diarrhea, hypokalemia, and hypochlorhydria. Its low incidence and high risk of malignancy pose a
Builes-Barrera, Carlos Alfonso +5 more
core